Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  Disease Landscape and Forecast Insights

Alzheimer’s Disease | Unmet Need | Agitation in Alzheimer’s Disease | US/EU | 2017

Login to access report north_east
Contact sales account_box

There is increased industry focus on the behavioral symptoms of Alzheimer’s disease (AD), including agitation—and with good reason. Agitation affects the majority of diagnosed AD patients, according to DRG epidemiology, and comprises a constellation of disruptive symptoms for patients and their families. With competing brands from Lundbeck/Otsuka, Avanir/Otsuka, and IntraCellular Therapies (among others) poised to enter the market beginning in 2021, and blockbuster sales at stake, understanding the drivers of clinical decision making in agitation and prescriber perceptions of the risk/benefits of today’s off-label (but generic) options will help identify levers for new product positioning and differentiation in this evolving market.

Questions Answered:

  • What are the treatment drivers and goals for agitation in AD?
  • What attributes are key influencers, which have limited impact, and which are hidden opportunities?
  • How do current therapies perform on key treatment drivers and goals for agitation in AD?
  • What are the prevailing areas of unmet need and opportunity in agitation in AD?
  • What trade-offs across different clinical attributes and price are acceptable to U.S. and European neurologists for a hypothetical new agitation in AD drug?

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 60 U.S. and 30 European neurologists fielded in January 2017

Key companies: Lundbeck, Otsuka Pharmaceutical, Avanir Pharmaceuticals

Key drugs: quetiapine, risperidone, olanzapine, haloperidol, citalopram, arpiprazole, lorazepam, brexpiprazole, AVP-786

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Chronic Pain – Current Treatment – Treatment Algorithms: Claims Data Analysis – Chronic Back Pain (US)
Approximately 30 million people in the United States have chronic back pain (CBP). Treatment of CBP poses a challenge to physicians owing to the heterogeneity of pain pathophysiology and the…
north_east
Report
Post-Traumatic Stress Disorder – Current Treatment – Treatment Algorithms: Claims Data Analysis – Post-Traumatic Stress Disorder (US)
Multiple guidelines recommend treating post-traumatic stress disorder (PTSD) first with psychotherapy. However, such approaches do not suffice for many patients, necessitating the use of…
north_east
Report
Alzheimer’s Disease – Landscape & Forecast – Disease Landscape & Forecast (G7)
Eisai / Biogen’s lecanemab (Leqembi) and Eli Lilly’s Kisunla (donanemab) have launched for the treatment of early Alzheimer’s disease (AD) in the United States and Japan and, after early…
north_east
Report
Postpartum Depression – Current Treatment – Treatment Algorithms: Claims Data Analysis – Postpartum Depression (US)
Postpartum depression (PPD) refers to depression experienced by women after childbirth. The PPD drug market consists of very limited treatment options specifically approved for PPD, so drugs used…
north_east
Report
Type 1 Diabetes – Current Treatment – Treatment Algorithms: Claims Data Analysis – Type 1 Diabetes (US)
Intensive insulin regimens have proven effective in delaying the progression of complications associated with untreated or poorly treated type 1 diabetes (T1D). Thus, insulin remains the…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east